Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 7/20 | 0.52 |
| ▸ | NPC1 | O15118 | 6/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.52 |
| ▸ | MAPT | P10636 | 4/20 | 0.50 |
| ▸ | ABL1 | P00519 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | ATM | Q13315 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.47 |
| ▸ | FAAH | O00519 | 3/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7434832 | 0.80 | CNR2 (0.57) | RAB9ANPC1KMT2APOLBATM | |
| SCHEMBL7437931 | 0.80 | GAA (0.62) | RAB9ANPC1KMT2AMAPTTDP1 | |
| SCHEMBL7438084 | 0.80 | NPC1 (0.71) | RAB9ANPC1KMT2AMAPTABL1 | |
| SCHEMBL3151233 | 0.79 | CYP2C9 (0.65) | RAB9ANPC1MAPTPOLBALDH1A1 | |
| SCHEMBL6764534 | 0.79 | NAMPT (0.61) | MAPTFAAH | |
| SCHEMBL6764523 | 0.77 | NPC1 (0.71) | RAB9ANPC1KMT2AMAPTALDH1A1 | |
| SCHEMBL6764498 | 0.76 | CNR2 (0.59) | — | |
| SCHEMBL12626568 | 0.76 | MAPT (0.79) | RAB9ANPC1KMT2AMAPTALDH1A1 | |
| SCHEMBL9466324 | 0.75 | RAB9A (0.63) | RAB9ANPC1KMT2AMAPTABL1 | |
| SCHEMBL723978 | 0.75 | RAB9A (0.63) | RAB9ANPC1KMT2AMAPTABL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8178560-B2 | Therapeutic agents useful for treating pain | PURDUE PHARMA L.P. (US) | 2012-05-15 | — | — | US | disclosed |
| US-20100331369-A1 | Therapeutic Agents Useful for Treating Pain | PURDUE PHARMA L.P. (US) | 2010-12-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100331369-A1 | Therapeutic Agents Useful for Treating Pain | GRIN1, GRIK1, GRIN2B | RAB9A 963/4885NPC1 748/4885KMT2A 2436/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.